<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237155</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02549-48</org_study_id>
    <nct_id>NCT04237155</nct_id>
  </id_info>
  <brief_title>French Source-monitoring Task</brief_title>
  <acronym>SOUMO</acronym>
  <official_title>Development of a Source-monitoring Task in French Adapted to Neuroimaging Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Source-monitoring is a cognitive process that refers to the ability to remember the source of
      an information. Source-monitoring processes are usually studied using experimental behavioral
      tasks. These tasks, which are very heterogeneous, are not all available in French and, for
      the most part, cannot be used in neuroimaging protocols.

      The aim of this project is to develop an experimental task which allows the measurement of
      source-monitoring performances, and which is adapted to neuroimaging protocols in a
      French-speaking population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 2 steps: 1) validation of the verbal material necessary for the
      creation of the source-monitoring task and 2) testing the task.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>For step 1, two populations of participants: 30 healthy volunteers and 30 patients with schizophrenia will have to complete a verbal material scoring questionnaire. For step 2, two populations of participants: 30 healthy volunteers and 30 patients with schizophrenia will have to complete the source-monitoring task which will be created from step 1 as well as the task of reference (Brunelin et al., 2008).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Source-monitoring performances</measure>
    <time_frame>one day</time_frame>
    <description>Performances (calculated as the number of accurate source responses and the number of errors) obtained at the new source-monitoring task and at the source-monitoring task of reference (Brunelin et al., 2006).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Healthy controls involved in step 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 healthy individuals will complete a verbal material scoring questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with schizophrenia involved in step 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients with schizophrenia will complete a verbal material scoring questionnaire</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls involved in step 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 healthy individuals will complete the source-monitoring task which will be created from step 1 as well as the task of reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with schizophrenia involved in step 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients with schizophrenia will complete the source-monitoring task which will be created from step 1 as well as the task of reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Subjects will complete a verbal material scoring questionnaire</description>
    <arm_group_label>Healthy controls involved in step 1</arm_group_label>
    <arm_group_label>Patients with schizophrenia involved in step 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive tests</intervention_name>
    <description>Subjects will complete two source-monitoring tasks: the source-monitoring task which will be created from step 1 as well as the task of reference</description>
    <arm_group_label>Healthy controls involved in step 2</arm_group_label>
    <arm_group_label>Patients with schizophrenia involved in step 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women aged between 18 and 45

          -  Having given their written informed consent

          -  Native French speakers

          -  Normal or corrected-to-normal vision

          -  Education level greater than or equal to 8 (in years)

          -  For the healthy control group, no history of previous diagnosed psychiatric disorders
             (according to the criteria of the Diagnostic and Statistical Manual of Mental
             Disorders - DSM5), absence of first-degree relatives diagnosed with spectrum disorder
             schizophrenia and bipolar disorder (DSM).

          -  For the schizophrenia patients group, meeting the DSM5 criteria for schizophrenia.

        Exclusion Criteria:

          -  Do not consent to be included in the study

          -  History of hearing impairments

          -  People who cannot read

          -  Presence of neurological or somatic diseases

          -  Being under tutorship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lydie Sartelet</last_name>
    <phone>0437915531</phone>
    <phone_ext>+33</phone_ext>
    <email>lydie.sartelet@ch-le-vinatier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier le Vinatier</name>
      <address>
        <city>Bron</city>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marine Mondino</last_name>
      <phone>0437915565</phone>
      <phone_ext>+33</phone_ext>
      <email>marine.mondino@ch-le-vinatier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérôme Brunelin</last_name>
      <phone>0437915297</phone>
      <phone_ext>+33</phone_ext>
      <email>jerome.brunelin@ch-le-vinatier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marine Mondino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Haesebaert</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerome Brunelin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sorce-monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

